References
- Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
- Stahl M, Tallman MS. Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all. Leuk Lymphoma. 2019;60(13):3107–3115.
- Reville PK, Kadia T. Individualizing treatment for newly diagnosed acute myeloid leukemia. Curr Treat Options Oncol. 2020;21(4):34.
- Kuwatsuka Y, Tomizawa D, Kihara R, et al. Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia. Int J Hematol. 2018;107(2):201–210.
- Long L, Assaraf YG, Lei ZN, et al. Genetic biomarkers of drug resistance: a compass of prognosis and targeted therapy in acute myeloid leukemia. Drug Resist Update. 2020;52:100703.
- Tsapogas P, Mooney C J, Brown G, et al. The cytokine Flt3-ligand in normal and malignant hematopoiesis. Int J Mol Sci. 2017;18(6):1115.
- Abou Dalle I, Ghorab A, Patel K, et al. Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3-mutant acute myeloid leukemia. Blood Cancer J. 2020;10(5):48.
- Kayamori K, Hagihara M, Kanda J, et al. Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia. Int J Hematol. 2019;110(5):566–574.
- Weiss AT, von Deetzen MC, Hecht W, et al. Molecular characterization of the feline T-cell receptor gamma alternate reading frame protein (TARP) ortholog. J Vet Sci. 2012;13(4):345–353.
- Clough E, Barrett T. The gene expression omnibus database. Methods Mol Biol. 2016;14(18):93–110.
- Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004;6(1):1–6.
- Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350(16):1617–1628.
- Bullinger L, Dohner K, Bair E, et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med. 2004;350(16):1605–1616.
- Verhaak RG, Wouters BJ, Erpelinck CA, et al. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica. 2009;94(1):131–134.
- Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–658.
- Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–404.
- Pourrajab F, Zare-Khormizi MR, Hekmatimoghaddam S, et al. Molecular targeting and rational chemotherapy in acute myeloid leukemia. J Exp Pharmacol. 2020;12:107–128.
- Valent P, Sadovnik I, Eisenwort G, et al. Immunotherapy-based targeting and elimination of leukemic stem cells in AML and CML. Int J Mol Sci. 2019;20(17):4233.
- Depreter B, Weening KE, Vandepoele K, et al. TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment. Haematologica. 2020;105(5):1306–1316.
- Fritzsche FR, Stephan C, Gerhardt J, et al. Diagnostic and prognostic value of T-cell receptor gamma alternative reading frame protein (TARP) expression in prostate cancer. Histol Histopathol. 2010;25(6):733–739.
- Rogers HJ, Wang X, Xie Y, et al. Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study. Am J Hematol. 2020;95(7):799–808.
- Pemmaraju N, Kantarjian H, Ravandi F, et al. Patient characteristics and outcomes in adolescents and young adults (AYA) with acute myeloid leukemia (AML). Clin Lymphoma Myeloma Leuk. 2016;16(4):213–222.